Workforce cuts continue at Bayer, with CEO Bill Anderson announcing on the company’s second-quarter earnings call on Aug. 6 that it expects more layoffs to come. These would follow the 2,000 employees it said it was letting go during first-quarter earnings and around 11,000 total since Bayer initiated a sweeping reorganization initiative in July 2023.
All entries for: Cardiology
August 7, 2025
Bayer
Layoffs
Whippany, NJ
50,001+ employees
Disease Area: Cardiology, Hematology, Multiple, Oncology
Drug Type: Biologic, Small Molecule
August 4, 2025
Merck
Layoffs
Rahway, NJ
10,001-50,000 employees
Merck projected it could let go of about 6,000 employees as part of a multiyear process, affecting around 8% of its global workforce, as part of its recently announced cost-cutting initiative.
Disease Area: Antiviral, Cardiology, Immune Diseases, Multiple, Neurological Diseases, Oncology
Drug Type: Biologic, Small Molecule
July 30, 2025
Merck
Layoffs
Rahway, NJ
10,001-50,000 employees
During the company’s second quarter earnings report, Merck CEO Rob Davis said that the company was undergoing a $3 billion cut in spending, spread across administrative, sales and research and development roles. The savings amount to about $1.7 billion annually, hoping to hit the $3 billion mark by 2027.
Disease Area: Antiviral, Cardiology, Immune Diseases, Multiple, Neurological Diseases, Oncology
Drug Type: Biologic, Small Molecule
July 28, 2025
Rocket Pharmaceuticals
Layoffs
Cranbury, NJ
201-500 employees
Rocket Pharmaceuticals is laying off 30% of its workforce in a strategic realignment initiative that also involves focusing resources on its late-stage heart disease programs, the company announced July 24. A total of 80 employees at Rocket’s Cranbury, New Jersey, site will be affected, according to a Workers Adjustment and Retraining Notification (WARN) Act notice. The layoffs will start Oct. 23 and continue through the end of the year, as per the WARN posting, and will allow Rocket to reduce its 12-month cash burn by almost 25%.
Disease Area: Cardiology, Immune Diseases, Multiple, Rare Diseases
Drug Type: Biologic
July 25, 2025
Genentech
Layoffs
San Francisco, CA
10,001-50,000 employees
Genentech is letting go of 87 employees at its South San Francisco headquarters, the second round of layoffs at the Roche subsidiary this year.
Disease Area: Cardiology, Hematology, Immune Diseases, Multiple, Neurological Diseases, Oncology
Drug Type: Biologic, Small Molecule
July 14, 2025
Azurity Pharmaceuticals
Layoffs
Wilmington, MA
501-1,000 employees
Azurity Pharmaceuticals is cutting 75 employees effective Sept. 12 through Dec. 31 in Wilmington, Massachusetts, according to a Worker Adjustment and Retraining Notification (WARN) Act notice. The specialty pharma company’s website lists that location as a manufacturing and operating facility.
Disease Area: Cardiology, Gastrointestinal, Multiple, Neurological Diseases
Drug Type: Small Molecule
July 3, 2025
4D Molecular Therapeutics - Emeryville
Layoffs
Emeryville, CA
51-200 employees
California-based 4D Molecular Therapeutics is downsizing by 25% its current and planned roles in an effort to better realign its resources, the company announced on Wednesday. The layoffs will primarily affect staff supporting early-stage R&D activities and will allow the company to “drive late-stage execution,” as per the announcement.
Disease Area: Cardiology, Multiple, Respiratory Diseases
Drug Type: Biologic
July 1, 2025
Bristol Myers Squibb - Lawrenceville
Layoffs
Lawrenceville, NJ
10,001-50,000 employees
Bristol Myers Squibb continues to aim its cost-cutting measures at Lawrenceville, New Jersey, laying off 68 employees there, according to a Worker Adjustment and Retraining Notification notice. The pharma has now let go of 1,223 people in Lawrenceville since April 2024, including 874 team members this year. The latest cuts will occur in multiple waves starting Sept. 25 and end Jan. 15, 2026. BMS has its headquarters and a location housing its commercialization and late-stage development teams in Lawrenceville. It was not immediately clear if the latest layoffs affect both sites.
Disease Area: Cardiology, Hematology, Immune Diseases, Multiple, Oncology
Drug Type: Biologic, Small Molecule
June 12, 2025
Genentech
Layoffs
San Francisco, CA
10,001-50,000 employees
Laying off 143 workers at their headquarters in South San Francisco.
Disease Area: Cardiology, Immune Diseases, Multiple, Neurological Diseases, Oncology, Rare Diseases
Drug Type: Biologic, Small Molecule
June 2, 2025
Stealth BioTherapeutics
Layoffs
Needham, MA
51-200 employees
To help direct resources toward a potential new drug application resubmission for Barth syndrome therapy elamipretide, Stealth BioTherapeutics has laid off 30% of its workforce, the company announced May 29. The Needham, Massachusetts–based biotech did not specify how many employees it let go, but its LinkedIn People page lists 65 associated members, meaning the cuts may have affected around 28 staffers.
Disease Area: Cardiology, Multiple, Neurological Diseases, Rare Diseases
Drug Type: Biologic, Small Molecule
